Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide versus spironolactone for female pattern hair loss
IRCT20260928071223N1Phase 3Recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in androgenetic alopecia (AGA) comparing Spironolactone with Bicalutamide (2 arms). Primary endpoints: Androgenic Alopecia Severity Score, Hair Shedding Score and 3 more. Started Oct 2026; status: recruiting.
02
Drugs
bicalutamidespironolactone
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on IRCT20260928071223N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260928071223N1.